2026-02-09, 7:22:54 a.m.
HERZLIYA, Israel and CALGARY, AB — February 9, 2026 — Leads & Copy — Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) has announced the publication of a research article in the peer-reviewed journal Frontiers in Veterinary Science.
The article, titled “Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial,” details key findings regarding Innocan’s LPT-CBD.
The study revealed a significant improvement in behavior/function reported by owners (p = 0.0217), with 100% of dogs showing improved function after LPT-CBD compared to 25% after placebo. Researchers also observed a significant reduction in lameness (Visual Lameness Scale; p = 0.033) and pain (interactive VAS; p = 0.005) following LPT-CBD administration compared to placebo.
According to the company, the LPT-CBD injection provided a sustained-release profile, with measurable plasma CBD concentrations lasting up to four weeks. All dogs tolerated LPT-CBD, with only minor, self-resolving adverse events, including a short-lived (~2-day) fever and a transient injection-site swelling that resolved within a few days without treatment.
In the study, eight client-owned dogs suffering from naturally occurring osteoarthritis received two subcutaneous injections in a randomized, blinded, crossover design: synthetic CBD in liposomes (LPT-CBD) 7 mg/kg and placebo (empty liposomes of identical amount and lipid composition) administered four weeks apart. Serial blood sampling was performed to assess CBD and its metabolite plasma concentrations and to evaluate hematological and biochemical profiles before and up to four weeks post-injections. Efficacy was assessed via activity monitoring collar and scorings by owners and two veterinary specialists.
The study demonstrated that a single subcutaneous injection of LPT-CBD produced sustained improvements in long-term pain-related outcomes and overall wellbeing in client-owned dogs with naturally occurring osteoarthritis for up to four weeks, with a statistically significant superiority over placebo. The observed clinical benefit is concordant with sustained plasma CBD concentrations persisting for up to four weeks following administration.
Professor Chezy Barenholz, Head of the Advisory Board, stated that LPT-CBD has been repeatedly demonstrated to have a pain relief effect across multiple efficacy studies in dogs, goats, and other animals. He noted the study shows the advantages of LPT-CBD over the liposomal placebo.
Dr. Eyal Kalo, Vice President of Research and Development, said the company is encouraged by these results, particularly given LPT-CBD’s potential as a long-acting approach to pain management in both veterinary and human settings. He added that Innocan has initiated discussions with the FDA, including the Center for Veterinary Medicine (CVM) and the human analgesic and anesthetic department of the FDA, to support the advancement of LPT-CBD across both markets.
Innocan is described as an innovator in the pharmaceuticals and wellness sectors, having developed a CBD-loaded liposome drug delivery platform for non-opioid pain management. They also develop and market self-care and beauty products. Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.
Source: Innocan Pharma Corporation
